- Achillion Pharmaceuticals (NASDAQ:ACHN) initiated with Sell rating and $4 (54% downside risk) price target by Chardan Capital.
- Rigel Pharmaceuticals (NASDAQ:RIGL) initiated with Buy rating and $6 (182% upside) price target by H.C. Wainwright.
- Aviragen Therapeutics (AVIR) initiated with Buy rating and $5 (178% upside) price target by H.C. Wainwright.
- Incyte (NASDAQ:INCY) initiated with Outperform rating by Berenberg.
- TearLab (NASDAQ:TEAR) initiated with Buy rating and $2 (167% upside) price target by Rodman & Renshaw.
- AstraZeneca (NYSE:AZN) initiated with Hold rating by Argus Research.
- Spark Therapeutics (NASDAQ:ONCE) initiated with Outperform rating and $70 (32% upside) price target by RBC Capital.
- Akari Therapeutics (NASDAQ:AKTX) initiated with Sell rating and $5 (55% downside risk) price target by Chardan Capital.